Chandan Healthcare

Chandan Healthcare delivered a solid Q3 FY26Current 6. Reported change: +6 vs prior year. with revenue of ₹65.77 CrCurrent ₹65.77 Cr. Reported change: +6 vs prior year. (+20Current reported value: 20. No comparable prior figure is available in the source record.% YoY) and EBITDA of ₹12.61 CrCurrent ₹12.61 Cr. Reported change: +6 vs prior year. (+39% YoY), driven by 34% growth in B2C diagnosticsCurrent 34% growth in B2C diagnostics. Reported change: +34% YoY.. EBITDA margin expanded 263 bps to 19.17%, despite a one-time gratuity provision of ₹2.2 Cr. PAT grew 8Current reported value: 8. No comparable prior figure is available in the source record.% to ₹4.54Current reported value: 4.54. No comparable prior figure is available in the source record. Cr. The company is aggressively expanding: 6 comprehensive centers and 18 labs opened YTD, with 9 more labs launching next month. A landmark 10-year government contract for radiology services in Punjab and Assam (₹55 CrCurrent ₹55 Cr. Reported change: New contract. annual revenue) will commence over the next six months. Management guided for significantly higher growth in FY27, with EBITDA margins expected to improve to 30-35% as new centers mature. Key risk: rapid expansion could strain working capital and employee costs, which rose to 18% of revenue this quarter.